LIFE aTyr Pharma

aTyr Pharma to Participate in October Virtual Investor Events

aTyr Pharma to Participate in October Virtual Investor Events
EN
07/10/2020

Underlying

LIFEaTyr Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on aTyr Pharma

 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of ...

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo...

September 15, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635...

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr’s common stock, each with an exercise price of $5.71 per share, which is eq...

September 5, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corpora...

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025. SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2025 results and provided a corporate update. “With the recent complet...

August 7, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of...

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis Topline results expected in the third quarter of 2025. SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last patient has completed their last visit in the Company’s Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod...

July 22, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. The Russell 3000® Ind...

June 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch